Literature DB >> 10854550

A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.

H Saito1, Y Soma, M Nakajima, J Koeda, H Kawaguchi, R Kakizaki, R Chiba, T Aisawa, A Munakata.   

Abstract

A case control study to evaluate the occult blood screening for colorectal cancer was conducted in a town where colorectal cancer screening had been performed by Hemoccult test during the early years and subsequently by an immunochemical hemagglutination test. All residents aged >/=40 years had been offered the annual screening. Case series consisted of 51 subjects with fatal colorectal cancer. Three controls per case were selected from the list of residents who were alive at the time of diagnosis of the corresponding case and had been living in the town, matched by gender and by age. The odds ratio (OR) of dying of colorectal cancer for those having their most recent screening histories with Hemoccult test or the immunochemical test during the preceding 1 year and 1-2 year segment before case diagnosis were 0.20 [95% confidence interval (CI): 0.08-0.49] and 0. 17 (95% CI: 0.04-0.75), respectively. The OR increased towards 1.0 as the number of years since the most recent screening increased. The OR of dying of colorectal cancer was calculated to be 0.19 (95% CI: 0.05-0.70) for those screened with the immunochemical test alone during the preceding 1 year after adjustment for previous screening histories with the Hemoccult test. Corresponding OR was 0.36 (95% CI: 0.11-1.17) for those screened with Hemoccult test during the preceding 1 year. These results suggest that screening for colorectal cancer by fecal occult blood testings or immunochemical test alone would reduce mortality and that efficacy of the screening would be higher for the immunochemical test than for Hemoccult test.

Entities:  

Mesh:

Year:  2000        PMID: 10854550     DOI: 10.3892/or.7.4.815

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial).

Authors:  Hiroshi Saito; Shin-Ei Kudo; Noriaki Takahashi; Seiichiro Yamamoto; Kenta Kodama; Koichi Nagata; Yuri Mizota; Fumio Ishida; Yasuo Ohashi
Journal:  Int J Colorectal Dis       Date:  2020-02-07       Impact factor: 2.571

2.  Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results.

Authors:  Kunihiko Wakamura; Shin-Ei Kudo; Hideyuki Miyachi; Kenta Kodama; Seiko Hayashi; Yasuharu Maeda; Yushi Ogawa; Yuta Kouyama; Shin-Ichi Kataoka; Kazuki Kato; Katsuro Ichimasa; Masashi Misawa; Yuichi Mori; Toyoki Kudo; Takemasa Hayashi; Fumio Ishida; Shogo Ohkoshi
Journal:  Mol Clin Oncol       Date:  2015-07-01

3.  Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test.

Authors:  Motoaki Kuriyama; Jun Kato; Koji Takemoto; Sakiko Hiraoka; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

4.  Perspectives of colorectal cancer screening in Germany 2009.

Authors:  Andreas Sieg; Kilian Friedrich
Journal:  World J Gastrointest Endosc       Date:  2009-10-15

5.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

6.  Medical costs according to the stages of colorectal cancer: an analysis of health insurance claims in Hachioji, Japan.

Authors:  Takahiro Utsumi; Takahiro Horimatsu; Yoshitaka Nishikawa; Nobuaki Hoshino; Yoshimitsu Takahashi; Rei Goto; Soichiro Kashihara; Jun Fukuyoshi; Takeo Nakayama; Hiroshi Seno
Journal:  J Gastroenterol       Date:  2021-07-03       Impact factor: 7.527

7.  Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.

Authors:  Jorja D Warren; Wei Xiong; Ashley M Bunker; Cecily P Vaughn; Larissa V Furtado; William L Roberts; John C Fang; Wade S Samowitz; Karen A Heichman
Journal:  BMC Med       Date:  2011-12-14       Impact factor: 8.775

8.  Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study.

Authors:  M Nakajima; H Saito; Y Soma; T Sobue; M Tanaka; A Munakata
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

9.  Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.

Authors:  G Castiglione; C B Visioli; S Ciatto; G Grazzini; A G Bonanomi; T Rubeca; P Mantellini; M Zappa
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

10.  Development of a Novel Scoring System for Predicting the Risk of Colorectal Neoplasia: A Retrospective Study.

Authors:  Tomohiko Ohno; Seiji Adachi; Mitsuru Okuno; Yohei Horibe; Naoe Goto; Midori Iwama; Osamu Yamauchi; Takao Kojima; Koshiro Saito; Takashi Ibuka; Ichiro Yasuda; Hiroshi Araki; Hisataka Moriwaki; Masahito Shimizu
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.